We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 145% below its sector, cheaper than its peers on earnings.
Honz Pharmaceutical Co., Ltd. is a Chinese enterprise based in Guangzhou, primarily engaged in the creation, production, and commercialization of pharmaceutical drugs. While specializing in pediatric medications, the company also provides treatments for adults across a broad spectrum of health concerns. Its product offerings address conditions such as allergic responses, digestive and diarrheal issues, respiratory problems like coughs and flu, fevers, various infections, fungal ailments, pain relief, and endocrine disorders. Honz Pharmaceutical distributes its products to the market via an extensive network of agents and numerous retail sales outlets. The company officially adopted its current name in November 2016, having previously operated as HaiNan Honz Pharmaceutical Co.,Ltd.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300086.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
